Roles of epithelial-mesenchymal transition in cancer drug resistance

Current Cancer Drug Targets

Volumn 13, Issue 9, 2013, Pages 915-929

  Shang, Yulong ^a   Cai, Xiqiang ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

BCL 2; Cancer stem cell; Drug resistance; EMT; MicroRNA; NF B; P glycoprotein

Indexed keywords

ABC TRANSPORTER; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 1; MICRORNA 145; MICRORNA 200; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SMAD2 PROTEIN; SORAFENIB; TAMOXIFEN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN;

BREAST CANCER; CANCER RESISTANCE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; OVARY CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84890821239     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113136660097     Document Type: Review

References (173)

1. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31, 1869-1883.
2. Foroni, C.; Broggini, M.; Generali, D.; Damia, G. Epithelialmesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38, 689-697.
3. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29, 4741-4751.
4. Voulgari, A.; Pintzas, A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796, 75-90.
5. Wang, Z.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A. S.; Kong, D.; Sarkar, F. H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 27-33.
6. Scheel, C.; Weinberg, R. A. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 2012, 22, 396-403.
7. Faux, M. C.; Coates, J. L.; Kershaw, N. J.; Layton, M. J.; Burgess, A. W. Independent interactions of phosphorylated β-catenin with E-cadherin at cell-cell contacts and APC at cell protrusions. PLoS One 2010, 5, e14127.
8. Yan, C.; Grimm, W. A.; Garner, W. L.; Qin, L.; Travis, T.; Tan, N.; Han, Y. P. Epithelialto mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am. J. Pathol. 2010, 176, 2247-2258.
9. Aomatsu, K.; Arao, T.; Abe, K.; Kodama, A.; Sugioka, K.; Matsumoto, K.; Kudo, K.; Kimura, H.; Fujita, Y.; Hayashi, H.; Nagai, T.; Shimomura, Y.; Nishio, K. Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2012, 53, 751-756.
10. Gal, A.; Sjöblom, T.; Fedorova, L.; Imreh, S.; Beug, H.; Moustakas, A. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 2008, 27, 1218-1230.
11. Maitah, M. Y.; Ali, S.; Ahmad, A.; Gadgeel, S.; Sarkar, F. H. Upregulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 2011, 6, e16068.
12. Heldin, C. H.; Vanlandewijck, M.; Moustakas, A. Regulation of EMT by TGFβ in cancer. FEBS Lett. 2012, 586, 1959-1970.
13. Xia, H.; Hui, K. M. MicroRNAs involved in regulating epithelialmesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012, 19, 723-730.
14. Li, F.; Liu, J.; Li, S. MicorRNA 106b ~ 25 cluster and gastric cancer. Surg. Oncol. 2013, 22(2), e7-10.
15. Yau, W. L.; Lam, C. S.; Ng, L.; Chow, A. K.; Chan, S. T.; Chan, J. Y.; Wo, J. Y.; Ng, K. T.; Man, K.; Poon, R. T.; Pang, R. W. Overexpression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS One 2013, 8, e57882.
16. Tao, Z. H.; Wan, J. L.; Zeng, L, Y.; Xie, L.; Sun, H. C.; Qin, L. X.; Wang, L.; Zhou, J.; Ren, Z. G.; Li, Y. X.; Fan, J.; Wu, W. Z. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J. Exp. Med. 2013, 210(4), 789-803.
17. Lee, J. Y.; Park, M. K.; Park, J. H.; Lee, H. J.; Shin, D. H.; Kang, Y.; Lee, C. H.; Kong, G. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 2013. [Epub ahead of print]
18. Paterson, E. L.; Kazenwadel, J.; Bert, A. G.; Khew-Goodall, Y.; Ruszkiewicz, A.; Goodall, G. J. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013, 15, 180-191.
19. Li, B. L.; Lu, C.; Lu, W.; Yang, T. T.; Qu, J.; Hong, X.; Wan, X. P. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med. Oncol. 2013, 30, 484.
20. Zhang, L. Y.; Liu, M.; Li, X.; Tang, H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J. Biol. Chem. 2013, 288, 4035-4047.
21. Guo, W.; Ren, D.; Chen, X.; Tu, X.; Huang, S.; Wang, M.; Song, L.; Zou, X.; Peng, X. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J. Cell Biochem. 2013, 114(7), 1606-1615.
22. Majid, S.; Dar, A. A.; Saini, S.; Arora, S.; Shahryari, V.; Zaman, M. S.; Chang, I.; Yamamura, S.; Tanaka, Y.; Deng, G.; Dahiya, R. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012, 72, 6435-6446.
23. Yokobori, T.; Suzuki, S.; Tanaka, N.; Inose, T.; Sohda, M.; Sano, A.; Sakai, M.; Nakajima, M.; Miyazaki, T.; Kato, H.; Kuwano, H. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2013, 104, 48-54.
24. Li, J.; Wang, Y.; Luo, J.; Fu, Z.; Ying, J.; Yu, Y.; Yu, W. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 2012, 586, 3761-3765.
25. Tucci, P.; Agostini, M.; Grespi, F.; Markert, E. K.; Terrinoni, A.; Vousden, K. H.; Muller, P. A.; Dötsch, V.; Kehrloesser, S.; Sayan, B. S.; Giaccone, G.; Lowe, S. W.; Takahashi, N.; Vandenabeele, P.; Knight, R. A.; Levine, A. J.; Melino, G. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109, 15312-15317.
26. Han, M.; Liu, M.; Wang, Y.; Chen, X.; Xu, J.; Sun, Y.; Zhao, L.; Qu, H.; Fan, Y.; Wu, C. Antagonism of miR-21 reverses epithelialmesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7, e39520.
27. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-offunction induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32(27), 3286-3295.
28. Cao, M.; Seike, M.; Soeno, C.; Mizutani, H.; Kitamura, K.; Minegishi, Y.; Noro, R.; Yoshimura, A.; Cai, L.; Gemma, A. MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int. J. Oncol. 2012, 41, 869-875.
29. Hur, K.; Toiyama, Y.; Takahashi, M.; Balaguer, F.; Nagasaka, T.; Koike, J.; Hemmi, H.; Koi, M.; Boland, C. R.; Goel, A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013, 62(9), 1315-1326.
30. Zhao, X.; Dou, W.; He, L.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y.; Wu, K.; Nie, Y.; Fan, D. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 2013, 32, 1363-1372.
31. Liu, Y. N.; Yin, J. J.; Abou-Kheir, W.; Hynes, P. G.; Casey, O. M.; Fang, L.; Yi, M.; Stephens, R. M.; Seng, V.; Sheppard-Tillman, H.; Martin, P.; Kelly, K. MiR-1 and miR-200 inhibit EMT via Slugdependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013, 32, 296-306.
32. Kurashige, J.; Kamohara, H.; Watanabe, M.; Hiyoshi, Y.; Iwatsuki, M.; Tanaka, Y.; Kinoshita, K.; Saito, S.; Baba, Y.; Baba, H. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann. Surg. Oncol. 2012, 19, 656-664.
33. Smith, A. L.; Iwanaga, R.; Drasin, D. J.; Micalizzi, D. S.; Vartuli, R. L.; Tan, A. C.; Ford, H. L. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012, 31, 5162-5171.
34. Stinson, S.; Lackner, M. R.; Adai, A. T.; Yu, N.; Kim, H. J.; O'Brien, C.; Spoerke, J.; Jhunjhunwala, S.; Boyd, Z.; Januario, T.; Newman, R. J.; Yue, P.; Bourgon, R.; Modrusan, Z.; Stern, H. M.; Warming, S.; de Sauvage, F. J.; Amler, L.; Yeh, R. F.; Dornan, D. TRPS1 targeting by miR-221/222 promotes the epithelial-tomesenchymal transition in breast cancer. Sci. Signal 2011, 4, ra41.
35. Su, J.; Zhang, A.; Shi, Z.; Ma, F.; Pu, P.; Wang, T.; Zhang, J.; Kang, C.; Zhang, Q. MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int. J. Oncol. 2012, 40, 1162-1170.
36. Jurmeister, S.; Baumann, M.; Balwierz, A.; Keklikoglou, I.; Ward, A.; Uhlmann, S.; Zhang, J. D.; Wiemann, S.; Sahin, Ö. MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol. Cell Biol. 2012, 32, 633-651.
37. Ahmad, A.; Aboukameel, A.; Kong, D.; Wang, Z.; Sethi, S.; Chen, W.; Sarkar, F. H.; Raz, A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011, 71, 3400-3409.
38. Kumarswamy, R.; Mudduluru, G.; Ceppi, P.; Muppala, S.; Kozlowski, M.; Niklinski, J.; Papotti, M.; Allgayer, H. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int. J. Cancer 2012, 130, 2044-2053.
39. Kim, N. H.; Kim, H. S.; Li, X. Y.; Lee, I.; Choi, H. S.; Kang, S. E.; Cha, S. Y.; Ryu, J. K.; Yoon, D.; Fearon, E. R.; Rowe, R. G.; Lee, S.; Maher, C. A.; Weiss, S. J.; Yook, J. I. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell. Biol. 2011, 195, 417-433.
40. Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Béchec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C. H.; Friederich, E. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010, 29, 4436-4448.
41. Li, Q. Q.; Chen, Z. Q.; Cao, X. X.; Xu, J. D.; Xu, J. W.; Chen, Y. Y.; Wang, W. J.; Chen, Q.; Tang, F.; Liu, X. P.; Xu, Z. D. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ. 2011, 18, 16-25.
42. Moes, M.; Le Béchec, A.; Crespo, I.; Laurini, C.; Halavatyi, A.; Vetter, G.; Del Sol, A.; Friederich, E. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One 2012, 7, e35440.
43. Fodale, V.; Pierobon, M.; Liotta, L.; Petricoin, E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011, 17, 89-95.
44. Chen, Q.; Zhang, T.; Wang, J. F.; Wei, D. Q. Advances in human cytochrome p450 and personalized medicine. Curr. Drug Metab. 2011, 12, 436-444.
45. Cerveny, L.; Svecova, L.; Anzenbacherova, E.; Vrzal, R.; Staud, F.; Dvorak, Z.; Ulrichova, J.; Anzenbacher, P.; Pavek, P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 2007, 35, 1032-1041.
46. Chen, Y.; Tang, Y.; Wang, M. T.; Zeng, S.; Nie, D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007, 67, 10361-10367.
47. Hendrikx, J. J.; Lagas, J. S.; Rosing, H.; Schellens, J. H.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int. J. Cancer 2013, 132, 2439-2447.
48. Zhu, H.; Liu, Z.; Tang, L.; Liu, J.; Zhou, M.; Xie, F.; Wang, Z.; Wang, Y.; Shen, S.; Hu, L.; Yu, L. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur. J. Pharmacol. 2012, 696, 43-53.
49. Zhang, D.; Fan, D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev. Anticancer Ther. 2007, 7, 1369-1378.
50. Hong, L.; Piao, Y.; Han, Y.; Wang, J.; Zhang, X.; Du, Y.; Cao, S.; Qiao, T.; Chen, Z.; Fan, D. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol. Cancer Ther. 2005, 4, 1936-1942.
51. Zhao, L.; Pan, Y.; Gang, Y.; Wang, H.; Jin, H.; Tie, J.; Xia, L.; Zhang, Y.; He, L.; Yao, L.; Qiao, T.; Li, T.; Liu, Z.; Fan, D. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J. Biol. Chem. 2009, 284, 26273-26285.
52. Zheng, W. E.; Chen, H.; Yuan, S. F.; Wu, L. L.; Zhang, W.; Sun, H. Y.; Chen, W. J. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J. BUON. 2012, 17, 284-290.
53. Yu, J.; Gao, J.; Lu, Z.; Li, Y.; Shen, L. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Med. Oncol. 2012, 29, 3029-3034.
54. Gao, J.; Lu, M.; Yu, J. W.; Li, Y. Y.; Shen, L. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 2011, 11, 177.
55. Xia, L.; Zhang, D.; Du, R.; Pan, Y.; Zhao, L.; Sun, S.; Hong, L.; Liu, J.; Fan, D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123, 372-379.
56. Bezler, M.; Hengstler, J. G.; Ullrich, A. Inhibition of doxorubicininduced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol. Oncol. 2012, 6, 516-529.
57. Song, L.; Xiong, H.; Li, J.; Liao, W.; Wang, L.; Wu, J.; Li, M. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin. Cancer Res. 2011, 17, 1839-1849.
58. Kim, T. R.; Cho, E. W.; Paik, S. G.; Kim, I. G. Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo-and radiation therapy. FEBS Lett. 2012, 586, 303-309.
59. O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J, Jr.; Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
60. Branch, P.; Masson, M.; Aquilina, G.; Bignami, M.; Karran, P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000, 19, 3138-3145.
61. Hengstler, J. G.; Pilch, H.;, Schmidt, M.; Dahlenburg, H.; Sagemüller, J.; Schiffer, I.; Oesch, F.; Knapstein, P. G.;, Kaina, B.; Tanner, B. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int. J. Cancer 2001, 95, 121-127.
62. Gadducci, A.; Cosio, S.; Muraca, S.; Genazzani, A. R. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur. J. Gynaecol. Oncol. 2002, 23, 390-396.
63. Knappskog, S.; Lønning PE. P53 and its molecular basis to chemoresistance in breast cancer. Expert Opin. Ther. Targets 2012, 16, 23-30.
64. Tapia, M.A.; González-Navarrete, I.; Dalmases, A.; Bosch, M.; Rodriguez-Fanjul, V.; Rolfe, M.; Ross, J. S.; Mezquita, J.; Mezquita, C.; Bachs, O.; Gascón, P.; Rojo, F.; Perona, R.; Rovira, A.; Albanell, J. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007, 6, 2284-2292.
65. Barlin, J. N.; Jelinic, P.; Olvera, N.; Bogomolniy, F.; Bisogna, M.; Dao, F.; Barakat, R. R.; Chi, D. S.; Levine, D. A. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol. Oncol. 2013, 128, 512-517.
66. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leuk. Res. 2008, 32, 1144-1147.
67. Bednarski, B. K.; Ding, X.; Coombe, K.; Baldwin, A. S.; Kim, H. J. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol. Cancer Ther. 2008, 7, 1827-1835.
68. Nakanishi, C.; Toi, M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297-309.
69. Catz, S. D.; Johnson, J. L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001, 20, 7342-7351.
70. Dai, Y.; Lawrence, T. S.; Xu, L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am. J. Transl. Res. 2009, 1, 1-15.
71. Chua, H. L.; Bhat-Nakshatri, P.; Clare, S. E.; Morimiya, A.; Badve, S.; Nakshatri, H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26, 711-724.
72. Hay, E. D. Role of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation. Cell Differ Dev. 1990, 32, 367-375.
73. Nauseef, J. T.; Henry, M. D. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat. Rev. Urol. 2011, 8, 428-439.
74. Li, Y.; VandenBoom, T. G. 2nd Kong, D.; Wang, Z.; Ali, S.; Philip, P. A.; Sarkar, F. H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.
75. Arumugam, T.; Ramachandran, V.; Fournier, K. F.; Wang, H.; Marquis, L.; Abbruzzese, J. L.; Gallick, G. E.; Logsdon, C. D.; McConkey, D. J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828.
76. Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138, 645-659.
77. Yao, Z.; Fenoglio, S.; Gao, D. C.; Camiolo, M.; Stiles, B.; Lindsted, T.; Schlederer, M.; Johns, C.; Altorki N.; Mittal, V.; Kenner, L.; Sordella, R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. USA 2010, 107, 15535-15540.
78. Liu, J.; Eischeid, A. N.; Chen, X. M. Col1A1 production and apoptotic resistance in TGF-1-induced epithelial-to-mesenchymal transition-like phenotype of 603B cells. PLoS One 2012, 7, e51371.
79. Kumar, A.; Xu, J.; Sung, B.; Kumar, S.; Yu, D.; Aggarwal, B. B.; Mehta, K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-tomesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012, 14, R4.
80. Kumar, A.; Xu, J.; Brady, S.; Gao, H.; Yu, D.; Reuben, J.; Mehta, K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5, e13390.
81. Huang, S.; Hölzel, M.; Knijnenburg, T.; Schlicker, A.; Roepman, P.; McDermott, U.; Garnett, M.; Grernrum, W.; Sun, C.; Prahallad, A.; Groenendijk, F. H.; Mittempergher, L.; Nijkamp, W.; Neefjes, J.; Salazar, R.; Ten Dijke, P.; Uramoto, H.; Tanaka, F.; Beijersbergen, R. L.; Wessels, L. F.; Bernards, R. MED12 controls the response to multiple cancer drugs through regulation of TGF-receptor signaling. Cell 2012, 151, 937-950.
82. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
83. Yang, A. D.; Fan, F.; Camp, E. R.; van Buren, G.; Liu, W.; Somcio, R.; Gray, M. J.; Cheng, H.; Hoff, P. M.; Ellis, L. M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12, 4147-4153.
84. Kajiyama, H.; Shibata, K.; Terauchi, M.; Yamashita, M.; Ino, K.; Nawa, A.; Kikkawa, F. Chemoresistance to paclitaxelinduces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31, 277-283.
85. Kim, M. R.; Choi, H. K.; Cho, K. B.; Kim, H. S.; Kang, K. W. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 2009, 100, 1834-1841.
86. Işeri, O. D.; Kars, M. D.; Arpaci, F.; Atalay, C.; Pak, I.; Gündüz, U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed. Pharmacother. 2011, 65, 40-45.
87. Ahmed, N.; Abubaker, K.; Findlay, J.; Quinn, M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 2010, 10, 268-278.
88. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K. K.; Gibson, N.; Haley, J. D. Epithelial to mesenchymal transition is a determinant of sensitivity of nonsmall-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 15, 9455-9462.
89. Uramoto, H.; Iwata, T.; Onitsuka, T.; Shimokawa, H.; Hanagiri, T.; Oyama, T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010, 30, 2513-2517.
90. Creighton, C. J.; Li, X.; Landis, M.; Dixon, J. M. Neumeister, V. M.; Sjolund, A.; Rimm, D. L.; Wong, H.; Rodriguez, A.; Herschkowitz, J. I.; Fan, C.; Zhang, X.; He, X.; Pavlick, A.; Gutierrez,; M. C.; Renshaw, L.; Larionov, A. A.; Faratian, D.; Hilsenbeck, S. G.; Perou, C. M.; Lewis, M. T.; Rosen, J. M.; Chang, J. C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106, 13820-13825.
91. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; KasimirBauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11, R46.
92. Gu, W.; Fang, F. F.; Li, B.; Cheng, B. B.; Ling, C. Q. Characterization and resistance mechanisms of a 5-fluorouracilresistant hepatocellular carcinoma cell line. Asian Pac. J. Cancer Prev. 2012, 13, 4807-4814.
93. van Malenstein, H.; Dekervel, J.; Verslype, C.; Van Cutsem, E.; Windmolders, P.; Nevens, F.; van Pelt, J. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-tomesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013, 329, 74-83.
94. Jiang, L.; Chan, J. Y.; Fung, K. P. Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2012, 422, 739-744.
95. Dennis, M.; Wang, G.; Luo, J.; Lin, Y.; Dohadwala, M.; Abemayor, E.; Elashoff, D. A.; Sharma, S.; Dubinett, S. M.; St John, M. A. Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngol. Head Neck Surg. 2012, 147, 726-732.
96. Marchini, S.; Fruscio, R.; Clivio, L.; Beltrame, L.; Porcu, L.; Nerini, I. F.; Cavalieri, D.; Chiorino, G.; Cattoretti, G.; Mangioni, C.; Milani, R.; Torri, V.; Romualdi, C.; Zambelli, A.; Romano, M.; Signorelli, M.; di Giandomenico, S.; D'Incalci, M. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 2013, 49, 520-530.
97. Leskelä, S.; Leandro-García, L. J.; Mendiola, M.; Barriuso, J.; Inglada-Pérez, L.; Muñoz, I.; Martínez-Delgado, B.; Redondo, A.; de Santiago, J.; Robledo, M.; Hardisson, D.; Rodríguez-Antona, C. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer 2010, 18, 85-95.
98. Puhr, M.; Hoefer, J.; Schäfer, G.; Erb, H. H.; Oh, S. J.; Klocker, H.; Heidegger, I.; Neuwirt, H.; Culig, Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 2012, 181, 2188-2201.
99. Zhu, K.; Chen, L.; Han, X.; Wang, J.; Wang, J. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells. Oncol. Rep. 2012, 27, 1027-1034.
100. Li, W.; Liu, C.; Tang, Y.; Li, H.; Zhou, F.; Lv, S. Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac. J. Cancer Prev. 2011, 12, 2575-2580.
101. Ieri, O. D.; Kars, M. D.; Gündüz, U. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol. Biol. Rep. 2012, 39, 3505-3516.
102. Cui, S. Y.; Huang, J. Y.; Chen, Y. T.; Song, H. Z.; Feng, B.; Huang, G. C.; Wang, R.; Chen, L. B.; De, W. Acquisition of chemo-or radioresistance and epithelial to mesenchymal transition (EMT) phenotypes in docetaxel-resistant lung adenocarcinoma cells was linked with downregulation of Let-7c. Mol. Cancer Res. 2013, 11(7), 699-713.
103. Milone, M. R.; Pucci, B.; Bruzzese, F.; Carbone, C.; Piro, G.; Costantini, S.; Capone, F.; Leone, A.; Di Gennaro, E.; Caraglia, M.; Budillon, A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis. 2013, 4, e641.
104. Cesi, V.; Casciati, A.; Sesti, F.; Tanno, B.; Calabretta, B.; Raschellà, G. TGFβ-induced c-Myb affects the expression of EMTassociated genes and promotes invasion of ER+ breast cancer cells. Cell Cycle 2011, 10, 4149-4161.
105. Sun, T.; Sun, B. C.; Zhao, X. L.; Zhao, N.; Dong, X. Y.; Che, N.; Yao, Z.; Ma, Y. M.; Gu, Q.; Zong, W. K.; Liu, Z. Y. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 2011, 54, 1690-1706.
106. Zhao, N.; Sun, B. C.; Zhao, X. L.; Liu, Z. Y.; Sun, T.; Qiu, Z. Q.; Gu, Q.; Che, N.; Dong, X. Y. Coexpression of Bcl-2 with epithelial-mesenchymal transition regulators is a prognostic indicator in hepatocellular carcinoma. Med. Oncol. 2012, 29, 2780-2792.
107. Pham, C. G.; Bubici, C.; Zazzeroni, F.; Knabb, J. R.; Papa, S.; Kuntzen, C.; Franzoso, G. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol. Cell Biol. 2007, 27, 3920-3935.
108. Huber, M. A.; Beug, H.; Wirth, T. Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle 2004, 3, 1477-1480.
109. Zhang, C.; Klymkowsky, M. W. Unexpected functional redundancy between Twist and Slug (Snail2) and their feedback regulation of NF-kappaB via Nodal and Cerberus. Dev. Biol. 2009, 331, 340-349.
110. Šošić, D.; Richardson, J. A.; Yu, K.; Ornitz, D. M.; Olson, E. N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 2003, 112, 169-180.
111. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
112. Al-Hajj, M.; Wicha, M. S.; ito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
113. Todaro, M.; Alea, M. P.; Di Stefano, A. B.; Cammareri, P.; Vermeulen, L.; Iovino, F.; Tripodo, C.; Russo, A.; Gulotta, G.; Medema, J. P.; Stassi, G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1, 389-402.
114. Singh, S. K.; Clarke, I. D.; Terasaki, M.; Bonn, V. E.; Hawkins, C.; Squire, J.; Dirks, P. B. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63, 5821-5828.
115. Gu, G.; Yuan, J.; Wills, M.; Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007, 67, 4807-4815.
116. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di, V. A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15, 504-514.
117. Zhang, S.; Balch, C.; Chan, M. W.; Lai, H. C.; Matei, D.; Schilder, J. M.; Yan, P. S.; Huang, T. H.; Nephew, K. P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68, 4311-4320.
118. Li, C.; Lee, C. J.; Simeone, D. M. Identification of human pancreatic cancer stem cells. Methods Mol. Biol. 2009, 568, 161-173.
119. Hermann, P. C.; Huber, S. L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, M.; Bruns, C. J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313-323.
120. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva. Chir. 2009, 64, 489-500.
121. Huang, E. H.; Hynes, M. J.; Zhang, T.; Ginestier, C.; Dontu, G.; Appelman, H.; Fields, J. Z.; Wicha, M. S.; Boman, B. M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69, 3382-3389.
122. Yi, J. M.; Tsai, H. C.; Glockner, S. C.; Lin, S.; Ohm, J. E.; Easwaran, H.; James, C. D.; Costello, J. F.; Riggins, G.; Eberhart, C. G.; Laterra, J.; Vescovi, A. L.; Ahuja, N.; Herman, J. G.; Schuebel, K. E.; Baylin, S. B. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008, 68, 8094-8103.
123. Yamashita, T.; Forgues, M.; Wang, W.; Kim, J. W.; Ye, Q.; Jia, H.; Budhu, A.; Zanetti, K. A.; Chen, Y.; Qin, L. X.; Tang, Z. Y.; Wang, X. W. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68, 1451-1461.
124. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D. G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67, 6796-6805.
125. Dirks, P. Invitation to a second round. Nature 2010, 466, 40-41.
126. Frank, N. Y.; Schatton, T.; Frank, M. H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest 2010, 120, 41-50.
127. Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A. S.; Kong, D.; Banerjee, S.; Sarkar, F. H. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat. 2010, 13, 109-118.
128. Saito, Y.; Uchida, N.; Tanaka, S.; Suzuki, N.; Tomizawa-Murasawa, M.; Sone, A.; Najima, Y.; Takagi, S.; Aoki, Y.; Wake, A.; Taniguchi, S.; Shultz, L. D.; Ishikawa, F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28, 275-280.
129. Shafee, N.; Smith, C. R.; Wei, S.; Kim, Y.; Mills, G. B.; Hortobagyi GN.; Stanbridge EJ.; Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68, 3243-3250.
130. To, K.; Fotovati, A.; Reipas, K. M.; Law, J. H.; Hu, K.; Wang, J.; Astanehe, A.; Davies, A. H.; Lee, L.; Stratford, A. L.; Raouf, A.; Johnson, P.; Berquin, I. M.; Royer, H. D.; Eaves, C. J.; Dunn, S. E. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70, 2840-2851.
131. Styczynski, J.; Drewa, T. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta. Biochim. Pol. 2007, 54, 717-726.
132. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D. G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and A. Cancer Res. 2005, 65, 6207-6219.
133. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
134. Mani, S. A.; Guo, W.; Liao, M. J.; Eaton, E. N.; Ayyanan, A.; Zhou, A. Y.; Brooks, M.; Reinhard, F.; Zhang, C. C.; Shipitsin, M.; Campbell, L. L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R. A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
135. DiMeo, T. A.; Anderson, K.; Phadke, P.; Fan, C.; Perou, C. M.; Naber, S.; Kuperwasser, C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelialmesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69, 5364-5373.
136. Brabletz, T.; Jung, A.; Spaderna, S.; Hlubek, F.; Kirchner, T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5, 744-749.
137. Floor, S.; van Staveren, W. C.; Larsimont, D.; Dumont, J. E.; Maenhaut, C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30, 4609-4621.
138. Chen, X.; Lingala, S.; Khoobyari, S.; Nolta, J.; Zern, M. A.; Wu, J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J. Hepatol. 2011, 55, 838-845.
139. Androutsellis-Theotokis, A.; Leker, R. R.; Soldner, F.; Hoeppner, D. J.; Ravin, R.; Poser, S. W.; Rueger, M. A.; Bae, S. K.; Kittappa, R.; McKay, R. D. Notch signaling regulates stem cell numbers in vitro and in vivo. Nature 2006, 442, 823-826.
140. Li, Y.; Maitah, M. Y.; Ahmad, A.; Kong, D.; Bao, B.; Sarkar, F. H. Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opin. Ther. Targets 2012, 16, 49-66.
141. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A. S.; Ali, S.; Abbruzzese, J. L.; Gallick, G. E.; Sarkar, F. H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407.
142. Xie, M.; Zhang, L.; He, C. S.; Xu, F.; Liu, J. L.; Hu, Z. H.; Zhao, L. P.; Tian, Y. Activation of Notch-1 enhances epithelialmesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem. 2012, 113, 1501-1513.
143. Palagani, V.; El Khatib, M.; Kossatz, U.; Bozko, P.; Müller, M. R.; Manns, M. P.; Krech, T.; Malek, N. P.; Plentz, R. R. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. PLoS One 2012, 7, e46514.
144. Li, J.; Zhou, B. P. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11, 49.
145. Scheel, C.; Eaton, E. N.; Li, S. H.; Chaffer, C. L.; Reinhardt, F.; Kah, K. J.; Bell, G.; Guo, W.; Rubin, J.; Richardson, A. L.; Weinberg, R. A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145, 926-940.
146. Day, T. F.; Yang, Y. Wnt and hedgehog signaling pathways in bone development. J. Bone Joint Surg. Am. 2008, 90, 19-24.
147. Wang, L.; Mezencev, R.; Bowen, N. J.; Matyunina, L. V.; McDonald, J. F. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol. Cell Biochem. 2012, 363, 257-268.
148. Liu, M.; Sakamaki, T.; Casimiro, M. C.; Willmarth, N. E.; Quong, A. A.; Ju, X.; Ojeifo, J.; Jiao, X.; Yeow, W. S.; Katiyar, S.; Shirley, L. A.; Joyce, D.; Lisanti, M. P.; Albanese, C.; Pestell, R. G. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 2010, 70, 10464-10473.
149. Iliopoulos, D.; Hirsch, H. A.; Struhl, K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139, 693-706.
150. Wellner, U.; Schubert, J.; Burk, U. C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V. G.; Morton, J.; Sansom, O.; Schüler, J.; Stemmler, M. P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11, 1487-1495.
151. Yang, X.; Lin, X.; Zhong, X.; Kaur, S.; Li, N.; Liang, S.; Lassus, H.; Wang, L.; Katsaros, D.; Montone, K.; Zhao, X.; Zhang, Y.; Bützow, R.; Coukos, G.; Zhang, L. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 2010, 70, 9463-9472.
152. Yu, C. C.; Chen, Y. W.; Chiou, G. Y.; Tsai, L. L.; Huang, P. I.; Chang, C. Y.; Tseng, L. M.; Chiou, S. H.; Yen, S. H.; Chou, M. Y.; Chu, P. Y.; Lo, W. L. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011, 47, 202-210.
153. Liu, Y.; Zhao, J.; Zhang, P. Y.; Zhang, Y.; Sun, S. Y.; Yu, S. Y.; Xi, Q. S. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med. Sci. Monit. 2012, 18, BR299-308.
154. Ibrahim, S. A.; Yip, G. W.; Stock, C.; Pan, J. W.; Neubauer, C.; Poeter, M.; Pupjalis, D.; Koo, C. Y.; Kelsch, R.; Schüle, R.; Rescher, U.; Kiesel, L.; Götte, M. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase-and E-cadherin-dependent mechanism. Int. J. Cancer 2012, 131, 884-896.
155. Louafi, F.; Martinez-Nunez, R. T.; Sanchez-Elsner, T.; MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J. Biol. Chem. 2010, 285, 41328-41336.
156. Hill, L.; Browne G.; Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int. J. Cancer 2013, 132, 745-754.
157. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D.; Bar-Eli, M.; Dinney, C. miR-200 expression regulates epithelial-tomesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15, 5060-5072.
158. Cittelly, D. M.; Dimitrova, I.; Howe, E. N.; Cochrane, D. R.; Jean, A.; Spoelstra, N. S.; Post MD.; Lu X.; Broaddus RR.; Spillman MA.; Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol. Cancer Ther. 2012, 11, 2556-2565.
159. Cochrane, D. R.; Spoelstra, N. S.; Howe, E. N.; Nordeen, S. K.; Richer, J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 2009, 8, 1055-1066.
160. Feng, B.; Wang, R.; Chen, L. B. Review of miR-200b and cancer chemosensitivity. Biomed. Pharmacother. 2012, 66, 397-402.
161. Wu, Y.; Xiao, Y.; Ding, X.; Zhuo, Y.; Ren, P.; Zhou, C.; Zhou, J. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance. PLoS One 2011, 6, e29043.
162. Berkers, J.; Govaere, O.; Wolter, P.; Beuselinck, B.; Schöffski, P.; van Kempen, L. C.; Albersen, M.; Van den Oord, J.; Roskams, T.; Swinnen, J.; Joniau, S.; Van Poppel, H.; Lerut, E. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-tomesenchymal transition and hypoxia resistance. J. Urol. 2013, 189(5), 1930-1938.
163. Manaka, Y.; Tsuchiya, S.; Sato, F.; Shimada, Y.; Shimizu, K.; Tsujimoto, G. MicroRNA-141 confers resistance to cisplatininduced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J. Hum. Genet. 2011, 56, 270-276.
164. Bhatnagar, N.; Li, X.; Padi, S. K.; Zhang, Q.; Tang, M. S.; Guo, B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1, e105.
165. Wang, B.; Herman-Edelstein, M.; Koh, P.; Burns, W.; Jandeleit-Dahm, K.; Watson, A.; Saleem, M.; Goodall, G. J.; Twigg, S. M.; Cooper, M. E.; Kantharidis, P. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010, 59, 1794-1802.
166. Kim, T.; Veronese, A.; Pichiorri, F.; Lee, T. J.; Jeon, Y. J.; Volinia, S.; Pineau, P.; Marchio, A.; Palatini, J.; Suh, S. S.; Alder, H.; Liu, C. G.; Dejean, A.; Croce, C. M. p53 regulates epithelialmesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208, 875-883.
167. Boni, V.; Bitarte, N.; Cristobal, I.; Zarate, R.; Rodriguez, J.; Maiello, E.; Garcia-Foncillas, J.; Bandres, E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol. Cancer Ther. 2010, 9, 2265-2275.
168. Husted, S.; Søkilde, R.; Rask, L.; Cirera, S.; Busk, P. K.; Eriksen, J.; Litman, T. MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. Mol. Pharm. 2011, 8, 2055-2062.
169. Franco, D. L.; Mainez, J.; Vega, S.; Sancho, P.; Murillo, M. M.; de Frutos, C. A.; Del Castillo, G.; López-Blau, C.; Fabregat, I.; Nieto, M. A. Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J. Cell Sci. 2010, 123, 3467-3477.
170. Kim, Y. J.; Hwang, J. S.; Hong, Y. B.; Bae, I.; Seong, Y. S. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res. 2012, 32, 799-806.
171. Hu, Q. D.; Chen, W.; Yan, T. L.; Ma, T.; Chen, C. L.; Liang, C.; Zhang, Q.; Xia, XF.; Liu, H.; Zhi, X.; Zheng, X. X.; Bai, X. L.; Yu, X. Z.; Liang, T. B. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012, 325, 207-213.
172. Sun, L.; Yao, Y.; Liu, B.; Lin, Z.; Lin, L.; Yang, M.; Zhang W.; Chen, W.; Pan, C.; Liu, Q.; Song, E.; Li, J. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012, 31, 432-445.
173. Rao, X.; Di Leva, G.; Li, M.; Fang, F.; Devlin, C.; Hartman-Frey C.; Burow ME.; Ivan M.; Croce CM.; Nephew KP. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30, 1082-1097.